Tandem Microfiltration for Recombinant Insulin Purification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Microfiltration processes in biopharmaceutical manufacturing face challenges in scaling up due to filter fouling and unpredictable performance, particularly in removing both soluble and insoluble impurities from recombinant insulin or insulin analogs, which affects the efficiency and purity of the final product.
Innovation Solution
A process involving two tandem microfiltration steps is implemented, where the first step precipitates the insulin or insulin analog, allowing for the removal of soluble impurities, and the second step solubilizes it, enabling the retention and removal of insoluble impurities, using pH adjustments and microfiltration with a 0.1 µm pore size membrane to achieve high purity and scalability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If a single microfiltration step is used, then the process is simple, but it cannot effectively remove both soluble and insoluble impurities
Solution Approach 1:
The microfiltration process is divided into two sequential steps: first microfiltration to remove soluble impurities from precipitated insulin, and second microfiltration to remove insoluble impurities from solubilized insulin. This segmentation allows each step to target specific impurity types, achieving comprehensive purification that a single step cannot accomplish.
2Manufacturing precision
If microfiltration is used to remove impurities, then purity improves, but filter fouling increases and reduces productivity
Solution Approach 1:
The process utilizes pH adjustments to change the solubility state of insulin between steps. By precipitating insulin at neutral pH and solubilizing at acidic pH, the process transforms the physical state of the product to facilitate different impurity removal mechanisms, reducing membrane fouling and improving processing efficiency.
Solution Approach 2:
The process employs periodic alternation between precipitation and solubilization phases. During precipitation phase, soluble impurities are removed; during solubilization phase, insoluble impurities are removed. This periodic action prevents continuous fouling and maintains sustained productivity throughout the purification process.
3Manufacturing precision
If pH adjustment is used to precipitate insulin, then soluble impurities can be removed, but additional process steps are required
Solution Approach 1:
pH adjustment serves multiple functions: it precipitates insulin for first microfiltration, enables solubilization for second microfiltration, and facilitates buffer exchange. This multi-functionality reduces the need for separate dedicated steps for each function, optimizing the overall process design.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly reduces both soluble and insoluble impurities, enhancing the purity of recombinant insulin or insulin analogs and facilitating their exchange into a suitable buffer for downstream purification, thereby improving the efficiency and scalability of the production process.
Implementation Method 1
applying the aqueous mixture to a surface of a microfilter having a pore exclusion size sufficient to retain the precipitated insulin or insulin analog thereto
Implementation Method 2
permeating the soluble impurities that are smaller than the exclusion pore size of the microfilter through the microfilter
Implementation Method 3
adjusting the pH of the aqueous solution from the digestion step to a pH sufficient to precipitate the insulin or insulin analog from the aqueous solution
Implementation Method 4
adjusting the pH to a pH sufficient to solubilize the precipitated insulin or insulin analog
Data Source
Figure 1A
Figure 1B
Figure 2
AI summary
The use of two tandem microfiltration (MF) steps in a process for making recombinant insulin is described. The two MF steps in a single downstream purification unit operation reduce both soluble and insoluble impurities and exchange the insulin product into a suitable buffer for downstream purification.